Journal
ANNUAL REVIEW OF MEDICINE, VOL 63
Volume 63, Issue -, Pages 171-183Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-050410-105655
Keywords
BRAF; vemurafenib; GSK2118436; MEK; CTLA-4
Categories
Ask authors/readers for more resources
Metastatic melanoma has historically been one of the most treatment-refractory types of cancer. Recent headway has been made in understanding the genetic underpinnings of this cancer. A subset of oncogenic events is amenable to targeting with drug therapy. BRAF-targeted therapies represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic knowledge. Ongoing translational research seeks to identify the most scientifically rational combination treatment strategies to build on single-agent targeted therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available